Extended Data Fig. 6: Pharmacokinetic study of B7H3xCD3xPDL1 in mice.
From: A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
C57BL/6 mice were administered an intraperitoneal (i.p.) dose of 5 mg/kg of B7H3xCD3xPDL1. Blood samples were collected at specified time points, and the concentrations of B7H3, CD3, and PDL1 antibodies were measured using ELISA. The pharmacokinetic profiles were analyzed to assess the stability and distribution of the antibodies over time, shown as individual profiles (a) and average profiles (b).
